Trastuzumab Deruxtecan for Breast Cancer NEJM
THB 0.00
trastuzumab Trastuzumab is a monoclonal antibody targeted against the HER2 tyrosine kinase receptor The majority of patients with metastatic breast
Trastuzumab is a biologic therapy indicated for the treatment of human epidermal growth factor receptor 2 -positive breast cancer and trastuzumab Trastuzumab is a biologic antineoplastic agent that, at the time of its FDA approval in 1998, was among the first available targeted chemotherapies
ปริมาณ:
trastuzumab Trastuzumab is a monoclonal antibody targeted against the HER2 tyrosine kinase receptor The majority of patients with metastatic breast
trastuzumab Trastuzumab is a biologic therapy indicated for the treatment of human epidermal growth factor receptor 2 -positive breast cancer and
Trastuzumab is a biologic antineoplastic agent that, at the time of its FDA approval in 1998, was among the first available targeted chemotherapies